2024
Dyspnea in a patient with metastatic breast cancer
Tarras E, Sen S, Wang H, Singh I. Dyspnea in a patient with metastatic breast cancer. CHEST Pulmonary 2024, 100074. DOI: 10.1016/j.chpulm.2024.100074.Peer-Reviewed Original ResearchTumoral Pulmonary Hypertension in a Patient With Metastatic Breast Cancer: Diagnostic Opportunity of the Right Heart Catheterization
Tarras E, Sen S, Wang H, Singh I. Tumoral Pulmonary Hypertension in a Patient With Metastatic Breast Cancer: Diagnostic Opportunity of the Right Heart Catheterization. 2024, a2208-a2208. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2208.Peer-Reviewed Original ResearchAssociation of cardiovascular diseases with cognitive performance in older adults
Park D, Jamil Y, Babapour G, Kim J, Campbell G, Akman Z, Kochar A, Sen S, Samsky M, Sikand N, Frampton J, Damluji A, Nanna M. Association of cardiovascular diseases with cognitive performance in older adults. American Heart Journal 2024, 273: 10-20. PMID: 38575050, PMCID: PMC11162917, DOI: 10.1016/j.ahj.2024.03.016.Peer-Reviewed Original ResearchAnimal Fluency TestOlder adultsCERAD-DRDSST scoresCardiovascular diseaseNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyCongestive heart failureFree of cardiovascular diseaseFluency testCardiovascular disease subtypesNutrition Examination SurveyAssociation of cardiovascular diseaseAnimal Fluency test scoreCognitive performanceLower cognitive performanceCoronary heart diseaseHeart failureCVD subtypesExamination SurveyAssess cognitive performanceAdultsCognitive functionHeart diseaseScoresThe management of heart failure cardiogenic shock: an international RAND appropriateness panel
Williams S, Kalakoutas A, Olusanya S, Schrage B, Tavazzi G, Carnicelli A, Montero S, Vandenbriele C, Luk A, Lim H, Bhagra S, Ott S, Farrero M, Samsky M, Kennedy J, Sen S, Agrawal R, Rampersad P, Coniglio A, Pappalardo F, Barnett C, Proudfoot A. The management of heart failure cardiogenic shock: an international RAND appropriateness panel. Critical Care 2024, 28: 105. PMID: 38566212, PMCID: PMC10988801, DOI: 10.1186/s13054-024-04884-5.Peer-Reviewed Original ResearchConceptsTemporary mechanical circulatory supportClinical practiceHF-CSCritical care admissionMulti-disciplinary panelRandomised controlled trialsClinical guidelinesAcutely decompensated chronic HFBackgroundObservational dataControlled trialsDecompensated chronic HFAppropriate methodologiesTrial designInternational expertsConclusionThis studyClinical trial designMechanical circulatory supportChronic HFCardiogenic shockClinical trialsAppropriate panelThoracic ultrasoundCirculatory supportLos AngelesPracticeAre Cardiac Myosin Inhibitors Useful in Patients With Hypertrophic Obstructive Cardiomyopathy and Comorbid Hypertension? ∗
Sikand N, Sen S. Are Cardiac Myosin Inhibitors Useful in Patients With Hypertrophic Obstructive Cardiomyopathy and Comorbid Hypertension? ∗. JACC Heart Failure 2024, 12: 580-582. PMID: 38448152, DOI: 10.1016/j.jchf.2023.12.021.Commentaries, Editorials and Letters
2023
Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction
Fuery M, Leifer E, Samsky M, Sen S, O'Connor C, Fiuzat M, Ezekowitz J, Piña I, Whellan D, Mark D, Felker G, Desai N, Januzzi J, Ahmad T. Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2023, 12: 479-487. PMID: 38127049, DOI: 10.1016/j.jchf.2023.11.007.Peer-Reviewed Original ResearchNT-proBNP measurementsPrimary trial endpointChronic heart failureNT-proBNP levelsReduced ejection fractionTrial endpointsHeart failureEjection fractionN-terminal pro-B-type natriuretic peptide (NT-proBNP) measurementBaseline NT-proBNP levelsChronic heart failure patientsNT-proBNP monitoringSecondary trial endpointsHeart failure hospitalizationNatriuretic peptide measurementHeart failure patientsCardiovascular deathFailure hospitalizationNT-proBNPFailure patientsPrognostic impactClinical outcomesPrognostic valueOutpatient sitesClinical studiesCirculating T cell specific extracellular vesicle profiles in cardiac allograft acute cellular rejection
Korutla L, Hoffman J, Rostami S, Hu R, Korutla V, Markmann C, Mullan C, Sotolongo A, Habertheuer A, Romano C, Acker M, Sen S, Agarwal D, Jayaraman A, Li B, Davis M, Naji A, Vallabhajosyula P. Circulating T cell specific extracellular vesicle profiles in cardiac allograft acute cellular rejection. American Journal Of Transplantation 2023, 24: 419-435. PMID: 38295008, DOI: 10.1016/j.ajt.2023.10.021.Peer-Reviewed Original ResearchAcute cellular rejectionAllogeneic transplant recipientsTransplant recipientsCellular rejectionHeart transplantationAlloreactive T cell activationEarly acute cellular rejectionT-cell receptor sequencingSyngeneic transplant recipientsCell receptor sequencingClinical heart transplantationT cell clonesNovel candidate biomarkersT cell activationQuantitative RT-PCRRecipient circulationOrgan transplantationT cellsVesicle profilesNoninvasive biomarkersCandidate biomarkersCell activationRegulatory markersDonor cardiomyocytesTransplantationHeart failure with reduced ejection fraction: clinical and economic burden and insights into current and emerging treatments.
Sen S. Heart failure with reduced ejection fraction: clinical and economic burden and insights into current and emerging treatments. The American Journal Of Managed Care 2023, 29: s180-s186. PMID: 37677742, DOI: 10.37765/ajmc.2023.89415.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyReduced ejection fractionHeart failureEjection fractionEconomic burdenManagement of HFrEFPresence of comorbiditiesEmergency department visitsVentricular ejection fractionDisease-modifying therapiesPoor treatment adherenceHealth care systemDepartment visitsMedical therapyPatient factorsComorbid conditionsMedication costsTreatment adherenceOptimal treatmentOutpatient carePreventable hospitalizationsIndividual patientsHigh riskTarget dosesMedical costsElectronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial
Ghazi L, Yamamoto Y, Fuery M, O'Connor K, Sen S, Samsky M, Riello R, Dhar R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial. European Heart Journal 2023, 44: 4233-4242. PMID: 37650264, DOI: 10.1093/eurheartj/ehad512.Peer-Reviewed Original ResearchGuideline-directed medical therapyAcute heart failureMineralocorticoid receptor antagonistsHeart failureElectronic health recordsGDMT prescriptionPrimary outcomeEnzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitorsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorElectronic health record alertsEvidence-based regimenProviders of patientsReduced ejection fractionCotransporter 2 inhibitorsRelevant patient characteristicsTime of dischargePre-specified criteriaAHF hospitalizationEligible patientsInpatient initiationPatient characteristicsEjection fractionHospitalized patientsMedian ageMulticenter study of universal prophylaxis versus pre‐emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation
Lerman J, Green C, Molina M, Maharaj V, Ortega‐Legaspi J, Sen S, Flattery M, Maziarz E, Shah K, Martin C, Alexy T, Shah P, Morris A, DeVore A, Cole R. Multicenter study of universal prophylaxis versus pre‐emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation. Clinical Transplantation 2023, 37: e15065. PMID: 37392192, PMCID: PMC10592402, DOI: 10.1111/ctr.15065.Peer-Reviewed Original ResearchConceptsAcute cellular rejectionCardiac allograft vasculopathyUniversal prophylaxisPreemptive therapyHeart transplantHT recipientsGrade 2RIntermediate riskCMV-related complicationsIncidence of leukopeniaPre-emptive therapyAnti-CMV therapyEnd-organ diseaseInitiation/escalationAllograft vasculopathyCellular rejectionCMV DNAemiaCMV preventionGraft outcomeHeart transplantationCMV infectionSecondary outcomesPrimary outcomeProphylaxis strategiesSuch patientsRisk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF
O’Connor K, Yamamoto Y, Sen S, Samsky M, Wilson F, Desai N, Ahmad T, Fuery M. Risk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF. JACC Heart Failure 2023, 11: 727-728. PMID: 37052546, DOI: 10.1016/j.jchf.2023.01.021.Peer-Reviewed Original ResearchUtilization of an Independent Procurement Team for Direct Procurement and Machine Perfusion of Cardiac Allografts Following Donation after Cardiac Death
Ragnarsson S, Morrison A, Higaki A, Mullan C, Sen S, Ahmad T, Anwer M, Geirsson A, Maulion C, Davis R. Utilization of an Independent Procurement Team for Direct Procurement and Machine Perfusion of Cardiac Allografts Following Donation after Cardiac Death. The Journal Of Heart And Lung Transplantation 2023, 42: s279-s280. DOI: 10.1016/j.healun.2023.02.638.Peer-Reviewed Original ResearchDCD heart transplantationCST groupCardiac allograftsHeart transplantationMachine perfusionNPS groupCardiac deathMedian warm ischemia timeExcellent short-term survivalMedian recipient agePostoperative mechanical supportSingle-center reviewMean donor ageWarm ischemia timeManual chart reviewShort-term survivalProcurement teamRecipient ageChart reviewCirculatory deathIschemia timeDonor ageOrgan recoveryHeartMate 3Group 52Atrial Fibrillation And Conduction Disease Are Associated With Cardiac Amyloidosis Subtypes
Patolia H, Chandramouli S, Cavalier J, Sen S, Arps K, Pokorney S, Karra R, Khouri M. Atrial Fibrillation And Conduction Disease Are Associated With Cardiac Amyloidosis Subtypes. Journal Of Cardiac Failure 2023, 29: 550-551. DOI: 10.1016/j.cardfail.2022.10.014.Peer-Reviewed Original ResearchAtrial fibrillationConduction diseaseVentricular tachycardiaCardiac amyloidosisHigh prevalencePresence of AFCross-sectional observational studyRight bundle branch blockHeart failure symptomsResults Patient characteristicsStandardized chart reviewSubtypes/genotypesPrevalence of arrhythmiasBundle branch blockLonger QRS intervalGenotype-related differencesATTR-CA patientsCardiac amyloidosis subtypesATTR-CMBaseline characteristicsChart reviewPatient characteristicsVentricular arrhythmiasAtrial arrhythmiasInfiltrative diseaseMulticenter Transthyretin Cardiac Amyloidosis Study Demonstrates Differences In Phenotype And Outcomes By Race
Cavalier J, Bhattacharya P, Patolia H, Chandramouli S, Sen S, Karra R, Maurer M, Khouri M. Multicenter Transthyretin Cardiac Amyloidosis Study Demonstrates Differences In Phenotype And Outcomes By Race. Journal Of Cardiac Failure 2023, 29: 699-700. DOI: 10.1016/j.cardfail.2022.10.381.Peer-Reviewed Original ResearchATTR-CM patientsReduced ejection fractionEjection fractionBlack patientsATTR-CMHeart failureWhite patientsAdvanced stageFindings merit further researchHigher NT-proBNP levelsMid-range ejection fractionNT-proBNP levelsNYHA class INYHA class IIILow ejection fractionRetrospective multicenter analysisTransthyretin amyloid cardiomyopathyLarge academic medical centerCross-sectional studyAcademic medical centerDeceased patientsMulticenter analysisWorsened prognosisRace patientsVital statusTrends and Outcomes in Cardiac Arrest Among Heart Failure Admissions
Chouairi F, Miller P, Loriaux D, Katz J, Sen S, Ahmad T, Fudim M. Trends and Outcomes in Cardiac Arrest Among Heart Failure Admissions. The American Journal Of Cardiology 2023, 194: 93-101. PMID: 36889986, DOI: 10.1016/j.amjcard.2023.01.012.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseCardiac arrestHospital cardiac arrestHF admissionsHF hospitalizationArtery diseaseHeart failureRenal diseasePrimary HF admissionsHeart failure admissionsHigher inpatient mortalityClinical Modification codesLong-term outcomesNational Inpatient SampleMultivariate logistic regressionHF patientsInpatient mortalityMultivariate adjustmentInpatient SampleFemale genderTenth RevisionHigher oddsLower oddsInternational ClassificationSerious eventsWHAT IS THE VALUE OF REPEATED NT-PROBNP MEASUREMENTS IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION?
Fuery M, Leifer E, Samsky M, Sen S, O'Connor C, Fiuzat M, Ezekowitz J, Pina I, Whellan D, Mark D, Felker G, Desai N, Januzzi J, Ahmad T. WHAT IS THE VALUE OF REPEATED NT-PROBNP MEASUREMENTS IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION? Journal Of The American College Of Cardiology 2023, 81: 624. DOI: 10.1016/s0735-1097(23)01068-9.Peer-Reviewed Original Research
2022
Clinical implications of Type 2 diabetes on outcomes after cardiac transplantation
Chouairi F, Mullan C, Ahmed A, Bhinder J, Guha A, Miller P, Jastreboff A, Fuery M, Chiravuri M, Geirsson A, Desai N, Maulion C, Sen S, Ahmad T, Anwer M. Clinical implications of Type 2 diabetes on outcomes after cardiac transplantation. PLOS ONE 2022, 17: e0273111. PMID: 36516178, PMCID: PMC9750001, DOI: 10.1371/journal.pone.0273111.Peer-Reviewed Original ResearchConceptsPost-transplant mortalityType 2 diabetesAllocation system changeOld allocation systemsHeart transplant recipientsOutcomes of patientsOrgan Sharing databaseProportion of patientsHeart transplantation outcomesLower likelihoodLikelihood of transplantationHigher likelihoodNew allocation systemCardiac transplantationHeart transplantationTransplant recipientsT2D patientsHeart failureSharing databaseCox regressionTransplantation outcomesUnited NetworkWorse outcomesT2DPatientsPragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial
Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAcute heart failureHeart failurePragmatic trialElectronic health recordsSubstantial health care costsBest practice advisoryReduced ejection fractionUsual care armHealth recordsTime of dischargeEvidence-based careHealth care costsClinical decision support systemAHF patientsCare armEligible patientsHF hospitalizationInpatient initiationCardiovascular deathMedication classesEjection fractionMedical therapyPrimary outcomePractice advisoryNetwork Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trialsSurvival After Heart Transplantation From SARS-CoV-2–Positive Donors
Mullan CW, Komlo C, Clark KAA, Sen S, Anwer M, Geirsson A, Ahmad T, Davis RP. Survival After Heart Transplantation From SARS-CoV-2–Positive Donors. JACC Heart Failure 2022, 10: 874-876. PMID: 36328657, PMCID: PMC9555312, DOI: 10.1016/j.jchf.2022.08.006.Peer-Reviewed Original Research